Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?

Investor Tips
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.

Articles You May Like

Amid inflation and market volatility, just 12% of adults — and 29% of millionaires — feel ‘wealthy’
‘A lot of people are going to see less money in their pocket.’ Here are must-know tax changes for 2022
‘Risky behaviors’ are causing credit scores to level off — here’s how that can hurt you
U.S. again delays deadline for Real IDs, until May 2025
The easiest way to travel full time? See what a 28-year-old paid for an apartment on a cruise ship